New insights into the mechanism of F-box proteins in colorectal cancer (Review)
- Authors:
- Jian Gong
- Jirong Huo
-
Affiliations: Department of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China - Published online on: February 27, 2015 https://doi.org/10.3892/or.2015.3823
- Pages: 2113-2120
This article is mentioned in:
Abstract
 |
 |
|
Center MM, Jemal A and Ward E: International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 18:1688–1694. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Center MM, Jemal A, Smith RA and Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin. 59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Coppedè F, Lopomo A, Spisni R and Migliore L: Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol. 20:943–956. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Shaik S, Dai X, Wu Q, Zhou X, Wang Z and Wei W: Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta. 1855:50–60. 2015. | |
|
Genschik P, Sumara I and Lechner E: The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): Cellular functions and disease implications. EMBO J. 32:2307–2320. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jadhav T and Wooten WM: Defining an embedded code for protein ubiquitination. J Proteomics Bioinform. 2:316–333. 2009. View Article : Google Scholar | |
|
Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M and Nakagawara A: UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 63:4167–4173. 2003.PubMed/NCBI | |
|
Hou YC: Role of E3 ubiquitin ligases in gastric cancer. World J Gastroenterol. 21:786–793. 2015.PubMed/NCBI | |
|
Zheng N, Schulman BA, Song L, et al: Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature. 416:703–709. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Nakayama KI and Nakayama K: Ubiquitin ligases: Cell-cycle control and cancer. Nat Rev Cancer. 6:369–381. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Santra MK, Wajapeyee N and Green MR: F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature. 459:722–725. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Agami R and Bernards R: Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell. 102:55–66. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F and Tetsu O: A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One. 1:e1282006. View Article : Google Scholar | |
|
Kumar R, Neilsen PM, Crawford J, et al: FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex. Cancer Res. 65:11304–11313. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Huang HL, Zheng WL, Zhao R, Zhang B and Ma WL: FBXO31 is down-regulated and may function as a tumor suppressor in hepatocellular carcinoma. Oncol Rep. 24:715–720. 2010.PubMed/NCBI | |
|
Zhang X, Kong Y, Xu X, et al: F-box protein FBXO31 is down-regulated in gastric cancer and negatively regulated by miR-17 and miR-20a. Oncotarget. 5:6178–6190. 2014.PubMed/NCBI | |
|
Kogo R, Mimori K, Tanaka F, Komune S and Mori M: FBXO31 determines poor prognosis in esophageal squamous cell carcinoma. Int J Oncol. 39:155–159. 2011.PubMed/NCBI | |
|
Zhang H, Kobayashi R, Galaktionov K and Beach D: p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell. 82:915–925. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Hershko D, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Krausz MM and Hershko A: Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer. 91:1745–1751. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K and Akiyoshi T: p27 expression and gastric carcinoma. Nat med. 3:5931997. View Article : Google Scholar : PubMed/NCBI | |
|
Fukuchi M, Masuda N, Nakajima M, Fukai Y, Miyazaki T, Kato H and Kuwano H: Inverse correlation between expression levels of p27 and the ubiquitin ligase subunit Skp2 in early esophageal squamous cell carcinoma. Anticancer Res. 24:777–783. 2004.PubMed/NCBI | |
|
Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K, Nakayama K and Mori M: Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 62:3819–3825. 2002.PubMed/NCBI | |
|
Yang G, Ayala G, De marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC and Harper JW: Elevated Skp2 protein expression in human prostate cancer: Association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 8:3419–3426. 2002.PubMed/NCBI | |
|
Lu M, Ma J, Xue W, et al: The expression and prognosis of FOXO3a and Skp2 in human hepatocellular carcinoma. Pathol Oncol Res. 15:679–687. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rose AE, Wang G, Hanniford D, et al: Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell melanoma Res. 24:197–206. 2011. View Article : Google Scholar | |
|
Tosco P, La Terra Maggiore GM, Forni P, Berrone S, Chiusa L and Garzino-Demo P: Correlation between Skp2 expression and nodal metastasis in stage I and II oral squamous cell carcinomas. Oral Dis. 17:102–108. 2011. View Article : Google Scholar | |
|
Einama T, Kagata Y, Tsuda H, et al: High-level Skp2 expression in pancreatic ductal adenocarcinoma: Correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Pancreas. 32:376–381. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Voduc D, Nielsen TO, Cheang MC and Foulkes WD: The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Hum Pathol. 39:1431–1437. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu CQ, Blackhall FH, Pintilie M, et al: Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker. Clin Cancer Res. 10:1984–1991. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J and Krek W: Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA. 98:5043–5048. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Latres E, Chiarle R, Schulman BA, Pavletich NP, Pellicer A, Inghirami G and Pagano M: Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA. 98:2515–2520. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Dowen SE, Scott A, Mukherjee G and Stanley MA: Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression. Int J Cancer. 105:326–330. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hershko DD and Shapira M: Prognostic role of p27Kip1 deregulation in colorectal cancer. Cancer. 107:668–675. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Shapira M, Ben-Izhak O, Bishara B, et al: Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma. Cancer. 100:1615–1621. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Li JQ, Wu F, Masaki T, Kubo A, Fujita J, Dixon DA, Beauchamp RD, Ishida T, Kuriyama S and Imaida K: Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors. Int J Oncol. 25:87–95. 2004.PubMed/NCBI | |
|
Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I and Hershko DD: The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer. 103:1336–1346. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Xu SY, Wang F, Wei G, et al: S-phase kinase-associated protein 2 knockdown blocks colorectal cancer growth via regulation of both p27 and p16 expression. Cancer Gene Ther. 20:690–694. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hristova NR, Tagscherer KE, Fassl A, Kopitz J and Roth W: Notch1-dependent regulation of p27 determines cell fate in colorectal cancer. Int J Oncol. 43:1967–1975. 2013.PubMed/NCBI | |
|
Tian YF, Chen TJ, Lin CY, et al: SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential. Tumour Biol. 34:1107–1117. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Vedin LL, Gustafsson JÅ and Steffensen KR: The oxysterol receptors LXRα and LXRβ suppress proliferation in the colon. Mol Carcinog. 52:835–844. 2013. View Article : Google Scholar | |
|
Wang Q, Zhou Y, Wang X and Evers BM: p27Kip1 nuclear localization and cyclin-dependent kinase inhibitory activity are regulated by glycogen synthase kinase-3 in human colon cancer cells. Cell Death Differ. 15:908–919. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Nishida N, Nagasaka T, Kashiwagi K, Boland CR and Goel A: High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther. 6:525–533. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kleivi K, Lind GE, Diep CB, et al: Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. Mol Cancer. 6:22007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu J, Li K, Dong L and Chen Y: Role of FBXL20 in human colorectal adenocarcinoma. Oncol Rep. 28:2290–2298. 2012.PubMed/NCBI | |
|
Zhu J, Deng S, Duan J, Xie X, Xu S, Ran M, Dai X, Pu Y and Zhang X: FBXL20 acts as an invasion inducer and mediates E-cadherin in colorectal adenocarcinoma. Oncol Lett. 7:2185–2191. 2014.PubMed/NCBI | |
|
Shirane M, Hatakeyama S, Hattori K and Nakayama K and Nakayama K: Common pathway for the ubiquitination of IkappaBalpha, IkappaBbeta, and IkappaBepsilon mediated by the F-box protein FWD1. J Biol Chem. 274:28169–28174. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Spiegelman VS, Slaga TJ, Pagano M, Minamoto T, Ronai Z and Fuchs SY: Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol Cell. 5:877–882. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang N, Wei P, Gong A, et al: Foxm1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell. 20:427–442. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mokkapati S, Niopek K, Huang L, Cunniff KJ, Ruteshouser EC, deCaestecker M, Finegold MJ and Huff V: β-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma. Cancer Res. 74:4515–4525. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM and Zhou BP: Stabilization of snail by NF-kappa B is required for inflammation-induced cell migration and invasion. Cancer Cell. 15:416–428. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, Donzelli M, Margottin-Goguet F, Jackson PK, Yamasaki L and Pagano M: Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell. 4:799–812. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kanarek N, Horwitz E, Mayan I, Leshets M, Cojocaru G, Davis M, Tsuberi BZ, Pikarsky E, Pagano M and Ben-Neriah Y: Spermatogenesis rescue in a mouse deficient for the ubiquitin ligase SCFβ-TrCP by single substrate depletion. Genes Dev. 24:470–477. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ougolkov A, Zhang B, Yamashita K, Bilim V, Mai M, Fuchs SY and Minamoto T: Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer. J Natl Cancer Inst. 96:1161–1170. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Koch A, Waha A, Hartmann W, Hrychyk A, Schüller U, Waha A, Wharton KA Jr, Fuchs SY, von Schweinitz D and Pietsch T: Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res. 11:4295–4304. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Müerköster S, Arlt A, Sipos B, Witt M, Grossmann M, Klöppel G, Kalthoff H, Fölsch UR and Schäfer H: Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res. 65:1316–1324. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Suresh Kumar KG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A and Fuchs SY: Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene. 26:1954–1958. 2007. View Article : Google Scholar : | |
|
Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F and Ben-Neriah Y: Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature. 396:590–594. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai WB, Chung YM, Zou Y, Park SH, Xu Z, Nakayama K, Lin SH and Hu MC: Inhibition of FOXO3 tumor suppressor function by betaTrCP1 through ubiquitin-mediated degradation in a tumor mouse model. PLoS One. 5:e111712010. View Article : Google Scholar : PubMed/NCBI | |
|
Nakayama K, Hatakeyama S, Maruyama S, Kikuchi A, Onoé K, Good RA and Nakayama KI: Impaired degradation of inhibitory subunit of NF-kappa B (I kappa B) and beta-catenin as a result of targeted disruption of the beta-TrCP1 gene. Proc Natl Acad Sci USA. 100:8752–8757. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Saitoh T and Katoh M: Expression profiles of βTRCP1 and βTRCP2, and mutation analysis of βTRCP2 in gastric cancer. Int J Oncol. 18:959–964. 2001.PubMed/NCBI | |
|
Kim CJ, Song JH, Cho YG, Kim YS, Kim SY, Nam SW, Yoo NJ, Lee JY and Park WS: Somatic mutations of the beta-TrCP gene in gastric cancer. APMIS. 115:127–133. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hartwell LH, Mortimer RK, Culotti J and Culotti M: Genetic control of the cell division cycle in yeast: V. genetic analysis of cdc mutants. Genetics. 74:267–286. 1973.PubMed/NCBI | |
|
Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O and Reed SI: Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature. 413:316–322. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter B and Reed SI: hCDC4 gene mutations in endometrial cancer. Cancer Res. 62:4535–4539. 2002.PubMed/NCBI | |
|
Matsumoto A, Onoyama I and Nakayama KI: Expression of mouse Fbxw7 isoforms is regulated in a cell cycle- or p53-dependent manner. Biochem Biophys Res Commun. 350:114–119. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Welcker M, Orian A, Grim JE, Eisenman RN and Clurman BE: A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr Biol. 14:1852–1857. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Crusio KM, King B, Reavie LB and Aifantis I: The ubiquitous nature of cancer: The role of the SCFFbw7 complex in development and transformation. Oncogene. 29:4865–4873. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S and Balmain A: Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature. 432:775–779. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Grim JE, Knoblaugh SE, Guthrie KA, et al: Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol. 32:2160–2167. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B and Lengauer C: Inactivation of hCDC4 can cause chromosomal instability. Nature. 428:77–81. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Stamatakos M, Palla V, Karaiskos I, Xiromeritis K, Alexiou I, Pateras I and Kontzoglou K: Cell cyclins: Triggering elements of cancer or not? World J Surg Oncol. 8:1112010. View Article : Google Scholar : PubMed/NCBI | |
|
Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA and Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogene. 8:2127–2133. 1993.PubMed/NCBI | |
|
Shinozaki H, Ozawa S, Ando N, Tsuruta H, Terada M, Ueda M and Kitajima M: Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res. 2:1155–1161. 1996.PubMed/NCBI | |
|
Ikeguchi M, Sakatani T, Ueta T and Kaibara N: Cyclin D1 expression and retinoblastoma gene protein (pRB) expression in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 127:531–536. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Sionov RV, Netzer E and Shaulian E: Differential regulation of FBXW7 isoforms by various stress stimuli. Cell Cycle. 12:3547–3554. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Grim JE, Gustafson m P, Hirata RK, Hagar AC, Swanger J, Welcker M, Hwang HC, Ericsson J, Russell DW and Clurman BE: Isoform- and cell cycle-dependent substrate degradation by the Fbw7 ubiquitin ligase. J Cell Biol. 181:913–920. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Van Drogen F, Sangfelt O, Malyukova A, Matskova L, Yeh E, Means AR and Reed SI: Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms. Mol Cell. 23:37–48. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sangfelt O, Cepeda D, Malyukova A, van Drogen F and Reed SI: Both SCFCdc4alpha and SCFCdc4gamma are required for cyclin E turnover in cell lines that do not overexpress cyclin E. Cell Cycle. 7:1075–1082. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tang X, Orlicky S, Lin Z, Willems A, Neculai D, Ceccarelli D, Mercurio F, Shilton BH, Sicheri F and Tyers M: Suprafacial orientation of the SCFCdc4 dimer accommodates multiple geometries for substrate ubiquitination. Cell. 129:1165–1176. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Welcker M and Clurman BE: Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell Div. 2:72007. View Article : Google Scholar : PubMed/NCBI | |
|
Iwatsuki M, Mimori K, Ishii H, et al: Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: Clinical significance. Int J Cancer. 126:1828–1837. 2010. | |
|
Fukushima H, Matsumoto A, Inuzuka H, et al: SCFFbw7 modulates the NFκB signaling pathway by targeting NFκB2 for ubiquitination and destruction. Cell Rep. 1:434–443. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Z, Zhou Y, Evers BM and Wang Q: Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells. Biochem Biophys Res Commun. 418:426–432. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Liu Y, Lu J, Zhang P, Wang Y, Xu Y, Wang Z, Mao JH and Wei G: Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells. Biochem Biophys Res Commun. 434:352–356. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tetzlaff MT, Yu W, Li M, Zhang P, Finegold M, Mahon K, Harper JW, Schwartz RJ and Elledge SJ: Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci USA. 101:3338–3345. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sancho R, Jandke A, Davis H, Diefenbacher ME, Tomlinson I and Behrens A: F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. Gastroenterology. 139:929–941. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Babaei-Jadidi R, Li N, Saadeddin A, et al: FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J Exp med. 208:295–312. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Davis H, Lewis A, Behrens A and Tomlinson I: Investigation of the atypical FBXW7 mutation spectrum in human tumours by conditional expression of a heterozygous propellor tip missense allele in the mouse intestines. Gut. 63:792–799. 2014. View Article : Google Scholar : | |
|
Jahid S, Sun J, Edwards RA, Dizon D, Panarelli NC, Milsom JW, Sikandar SS, Gümüs ZH and Lipkin SM: miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov. 2:540–553. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Akhoondi S, Lindström L, Widschwendter M, Corcoran M, Bergh J, Spruck C, Grandér D and Sangfelt O: Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res. 12:R1052010. View Article : Google Scholar | |
|
Kemp Z, Rowan A, Chambers W, et al: CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. Cancer Res. 65:11361–11366. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mouradov D, Domingo E, Gibbs P, et al: Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol. 108:1785–1793. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Miyaki M, Yamaguchi T, Iijima T, Takahashi K, Matsumoto H and Mori T: Somatic mutations of the CDC4 (FBXW7) gene in hereditary colorectal tumors. Oncology. 76:430–434. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Voorham QJ, Carvalho B, Spiertz AJ, et al: Comprehensive mutation analysis in colorectal flat adenomas. PLoS One. 7:e419632012. View Article : Google Scholar : PubMed/NCBI | |
|
Xie T, Cho YB, Wang K, et al: Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing. Genomics. 104:234–241. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jardim DL, Wheler JJ, Hess K, et al: FBXW7 mutations in patients with advanced cancers: Clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One. 9:e893882014. View Article : Google Scholar : PubMed/NCBI | |
|
Sung JJ, Ng SC, Chan FK, et al: An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut. 64:121–132. 2015. View Article : Google Scholar | |
|
Wertz IE, Kusam S, Lam C, et al: Sensitivity to antitubulin chemotherapeutics is regulated by mCL1 and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Alinari L, White VL, Earl CT, et al: Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs. 1:31–40. 2009. View Article : Google Scholar : | |
|
Kane RC, Bross PF, Farrell AT and Pazdur R: Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 8:508–513. 2003. View Article : Google Scholar : PubMed/NCBI |
